Overview: ATP-binding cassette transporters are ubiquitous membrane proteins characterized by facilitated movement of a range of substrates, including ions, lipids, peptides, steroids. The functional transporter is probably dimeric, with individual subunits typically made up of two groups of 6TM-spanning domains, with two nucleotide-binding domains (NBD). The majority of eukaryotic ATP-binding cassette (ABC) transporters are ‘full’ transporters incorporating both TM and NBD entities. Some ABCs, notably the ABCD family, appear relatively truncated and are only functional as homo- or heterodimers. Eukaryotic ABC transporters convey substrates from the cytoplasm, either out of the cell or into intracellular organelles. Their role in the efflux of exogenous compounds, notably chemotherapeutic agents, has led to considerable interest.
| Systematic name | Common abbreviation | Other names | Ensembl ID | Comments |
|---|---|---|---|---|
| ABCA1 | ABC1, CERP | Cholesterol efflux regulatory protein | ENSG00000165029 | Loss-of-function mutations are associated with Tangier disease, in which plasma HDL cholesterol levels are greatly reduced |
| ABCA2 | ABC2 | – | ENSG00000107331 | – |
| ABCA3 | ABC3, ABCC | – | ENSG00000167972 | Loss-of-function mutations are associated with pulmonary surfactant deficiency |
| ABCA4 | ABCR | Retinal-specific ATP-binding cassette transporter, RIM ABC transporter, RmP, Stargardt disease protein | ENSG00000198691 | Retinal-specific transporter of N-retinylPE; loss-of-function mutations are associated with Stargardt disease, a juvenile onset macular degenerative disease |
| ABCA5 | – | – | ENSG00000154265 | – |
| ABCA6 | – | – | ENSG00000154262 | – |
| ABCA7 | – | – | ENSG00000064687 | – |
| ABCA8 | – | KIAA0822 | ENSG00000141338 | – |
| ABCA9 | – | – | ENSG00000154258 | – |
| ABCA10 | – | – | ENSG00000154263 | – |
| ABCA12 | – | – | ENSG00000144452 | Reported to play a role in skin ceramide formation (Zuo et al., 2008) |
| ABCA13 | – | – | ENSG00000179869 | – |
| ABCA14 | – | – | ENSMUSG00000062017 | No orthologue in man |
| ABCA15 | – | – | ENSMUSG00000054746 | No orthologue in man |
| ABCA16 | – | – | ENSMUSG00000051900 | No orthologue in man |
| ABCA17 | – | – | ENSMUSG00000035435 | No orthologue in man |
| ABCB1 | MDR1, PGP1 | Multi-drug resistance protein 1, P-glycoprotein 1, CD243 antigen | ENSG00000085563 | Responsible for the cellular export of many therapeutic drugs |
| ABCB2 | TAP1 | Antigen peptide transporter 1, APT1, peptide transporter TAP1, peptide supply factor 1 (PSF-1), peptide transporter involved in antigen processing 1 | ENSG00000168394 | Endoplasmic reticulum, possibly as heterodimer with TAP2 |
| ABCB3 | TAP2 | Antigen peptide transporter 2 (APT2), Peptide transporter TAP2, peptide supply factor 2 (PSF-2), peptide transporter involved in antigen processing 2 | ENSG00000204267 | Endoplasmic reticulum, possibly as heterodimer with TAP1 |
| ABCB4 | PGY3 | Multi-drug resistance protein 3, P-glycoprotein 3 | ENSG00000005471 | Transports PC from intracellular to extracellular face of the hepatocyte canalicular membrane (Oude Elferink and Paulusma, 2007) |
| ABCB5 | – | P-glycoprotein ABCB5 | ENSG00000004846 | – |
| ABCB6 | MTABC3 | Mitochondrial ABC transporter 3, ubiquitously expressed mammalian ABC half transporter, P-glycoprotein-related protein | ENSG00000115657 | Mitochondrial |
| ABCB7 | ABC7 | – | ENSG00000131269 | Mitochondrial; reportedly essential for haematopoiesis (Pondarre et al., 2007) |
| ABCB8 | MABC1 | – | ENSG00000197150 | Mitochondrial; suggested to play a role in chemoresistance of melanoma (Elliott and Al-Hajj, 2009) |
| ABCB9 | TAPL | TAP-like protein, hABCB9 | ENSG00000150967 | Reported to be lysosomal (Kamakura et al., 2008) |
| ABCB10 | MTABC2 | Mitochondrial ABC transporter 2 | ENSG00000135776 | Mitochondrial |
| ABCB11 | ABC16 | Bile salt export pump, BSEP, PFIC-2, PFIC2, PGY4, SPGP | ENSG00000073734 | Loss-of-function mutations are associated with familial intrahepatic cholestasis (Stieger, 2009) |
| ABCC1 | MRP1 | Multidrug resistance-associated protein 1, Leukotriene C4 transporter | ENSG00000103222 | Exhibits a broad substrate specificity (Bakos and Homolya, 2007) |
| ABCC2 | MRP2, cMOAT | Multidrug resistance-associated protein 2, Canalicular multispecific organic anion transporter 1, Canalicular multidrug resistance protein | ENSG00000023839 | Loss-of-function mutations are associated with Dubin-Johnson syndrome, in which plasma levels of conjugated bilirubin are elevated |
| ABCC3 | MRP3 | Multidrug resistance-associated protein 3, Canalicular multispecific organic anion transporter 2, Multi-specific organic anion transporter-D, MOAT-D | ENSG00000108846 | Transports conjugates of glutathione, sulphate or glucuronide (see Borst et al., 2007) |
| ABCC4 | MRP4 | Multidrug resistance-associated protein 4, Multi-specific organic anion transporter-B, MOAT-B | ENSG00000125257 | Although reported to facilitate cellular cyclic nucleotide export, this role has been questioned (see Borst et al., 2007); reported to export prostaglandins in a manner sensitive to NSAIDS (Reid et al., 2003) |
| ABCC5 | MRP5 | Multidrug resistance-associated protein 5, Multi-specific organic anion transporter-C, MOAT-C, pABC11, SMRP | ENSG00000114770 | Although reported to facilitate cellular cyclic nucleotide export, this role has been questioned (see Borst et al., 2007) |
| ABCC6 | MRP6 | Multidrug resistance-associated protein 6, Anthracycline resistance-associated protein, Multi-specific organic anion transporter-E, MOAT-E | ENSG00000091262 | – |
| ABCC7 | CFTR | Cystic fibrosis transmembrane conductance regulator, cAMP-dependent chloride channel | ENSG00000001626 | See page S131 |
| ABCC8 | SUR1 | Sulfonylurea receptor 1 | ENSG00000006071 | See page S141 |
| ABCC9 | SUR2 | Sulfonylurea receptor 2 | ENSG00000069431 | See page S141 |
| ABCC10 | MRP7 | Multidrug resistance-associated protein 7 | ENSG00000124574 | – |
| ABCC11 | MRP8 | Multidrug resistance-associated protein 8 | ENSG00000121270 | Single nucleotide polymorphisms distinguish wet vs. dry earwax; reported to export chemotherapeutic nucleotides (Oguri et al., 2007) |
| ABCC12 | MRP9 | Multidrug resistance-associated protein 9 | ENSG00000140798 | – |
| ABCC13 | Putative ATP-binding cassette transporter C13 | ENSG00000155288 | A possible pseudogene | |
| ABCD1 | ALDP | Adrenoleukodystrophy protein | ENSG00000101986 | Peroxisomal |
| ABCD2 | ALDR | Adrenoleukodystrophy- related protein, adrenoleukodystrophy-like 1 | ENSG00000173208 | Peroxisomal |
| ABCD3 | PMP70 | 70 kDa peroxisomal membrane protein, PXMP1 | ENSG00000117528 | Peroxisomal |
| ABCD4 | PMP69 | Peroxisomal membrane protein 69, peroxisomal membrane protein 1-like, PXMP1-L, P70R | ENSG00000119688 | Peroxisomal |
| ABCE1 | OABP | RNase L inhibitor, ribonuclease 4 inhibitor, RNS4I, 2′-5′ oligoadenylate-binding protein | ENSG00000164163 | Lacks transport function |
| ABCF1 | ABC50 | TNF-α-stimulated ABC protein | ENSG00000204574 | Lacks transport function |
| ABCF2 | Iron-inhibited ABC transporter 2 | ENSG00000033050 | Lacks transport function | |
| ABCF3 | ENSG00000161204 | Lacks transport function | ||
| ABCG1 | ABC8 | White protein homolog | ENSG00000160179 | – |
| ABCG2 | ABCP | Placenta-specific ATP-binding cassette transporter, breast cancer resistance protein, BCRP, mitoxantrone resistance-associated protein, MXR, CD338 antigen, CDw338 | ENSG00000118777 | – |
| ABCG4 | White2 | ENSG00000172350 | – | |
| ABCG5 | White3, Sterolin-1 | ENSG00000138075 | – | |
| ABCG8 | Sterolin-2 | ENSG00000143921 | – |
ABCC8 and ABCC9 are unusual in that they lack transport capacity but regulate the activity of particular K+ channels (Kir6.1-6.2), conferring nucleotide sensitivity to these channels to generate the canonical KATP channels.
Glossary
Abbreviations:
- ABC
ATP-binding cassette
- NBD
nucleotide-binding domain
- N-retinylPE
N-retinylphosphatidylethanolamine
- NSAID
non-steroidal anti-inflammatory drugs
- PC
phosphatidylcholine
Further Reading
Aye IL, Singh AT, Keelan JA (2009). Transport of lipids by ABC proteins: interactions and implications for cellular toxicity, viability and function. Chem Biol Interact180: 327–339.
Borst P, de Wolf C, van de Wetering K (2007). Multidrug resistance–associated proteins 3, 4, and 5. Pflugers Arch453: 661–673.
Bryan J, Munoz A, Zhang X, Dufer M, Drews G, Krippeit–Drews P et al. (2007). ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch453: 703–718.
Ecker GF, Stockner T, Chiba P (2008). Computational models for prediction of interactions with ABC–transporters. Drug Discov Today13: 311–317.
Linton KJ, Higgins CF (2007). Structure and function of ABC transporters: the ATP switch provides flexible control. Pflugers Arch453: 555–567.
Procko E, O'Mara ML, Bennett WF, Tieleman DP, Gaudet R (2009). The mechanism of ABC transporters: general lessons from structural and functional studies of an antigenic peptide transporter. FASEB J23: 1287–1302.
Ravna AW, Sager G (2009). Molecular modeling studies of ABC transporters involved in multidrug resistance. Mini Rev Med Chem9: 186–193.
Rees DC, Johnson E, Lewinson O (2009). ABC transporters: the power to change. Nat Rev Mol Cell Biol10: 218–227.
Russel FG, Koenderink JB, Masereeuw R (2008). Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci29: 200–207.
Schrickx JA, Fink-Gremmels J (2008). Implications of ABC transporters on the disposition of typical veterinary medicinal products. Eur J Pharmacol585: 510–519.
Seeger MA, van Veen HW (2009). Molecular basis of multidrug transport by ABC transporters. Biochim Biophys Acta1794: 725–737.
Sharom FJ (2008). ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics9: 105–127.
Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug Discov Today13: 379–393.
Wanders RJ, Visser WF, van Roermund CW, Kemp S, Waterham HR (2007). The peroxisomal ABC transporter family. Pflugers Arch453: 719–734.
References
- Bakos E, Homolya L. Pflugers Arch. 2007;453:621–641. doi: 10.1007/s00424-006-0160-8. [DOI] [PubMed] [Google Scholar]
- Elliott AM, Al-Hajj MA. Mol Cancer Res. 2009;7:79–87. doi: 10.1158/1541-7786.MCR-08-0235. [DOI] [PubMed] [Google Scholar]
- Kamakura A, et al. Biochem Biophys Res Commun. 2008;377:847–851. doi: 10.1016/j.bbrc.2008.10.078. [DOI] [PubMed] [Google Scholar]
- Oguri T, et al. Mol Cancer Ther. 2007;6:122–127. doi: 10.1158/1535-7163.MCT-06-0529. [DOI] [PubMed] [Google Scholar]
- Oude Elferink RP, Paulusma CC. Pflugers Arch. 2007;453:601–610. doi: 10.1007/s00424-006-0062-9. [DOI] [PubMed] [Google Scholar]
- Pondarre C, et al. Blood. 2007;109:3567–3569. doi: 10.1182/blood-2006-04-015768. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reid G, et al. Proc Natl Acad Sci USA. 2003;100:9244–9249. doi: 10.1073/pnas.1033060100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stieger B. Curr Opin Lipidol. 2009;20:176–181. doi: 10.1097/MOL.0b013e32832b677c. [DOI] [PubMed] [Google Scholar]
- Zuo Y, et al. J Biol Chem. 2008;283:36624–36635. doi: 10.1074/jbc.M807377200. [DOI] [PMC free article] [PubMed] [Google Scholar]
